Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

The Mechanisms By Which Mutant-NPM1 Uncouples Differentiation from Proliferation Are Reversed By Several Drugs, Enabling Rational Multi-Component Non-Cytotoxic Differentiation Therapy

Xiaorong Gu, PhD, Quteba Ebrahem, MD, Reda Z. Mahfouz, MD PhD, Metis Hasipek, PhD, Francis Enane, PhD, Tomas Radivoyevitch, Nicolas Rapin, PhDMSc, Bartlomiej P. Przychodzen, MSc, Ramesh Balusu, PhD, Claudiu V Cotta, David Wald, MD PhD, Zhenbo Hu, MD PhD, Yosef Landesman, PhD, Maria Paola Martelli, MD PhD, Brunangelo Falini, MD, Hetty E. Carraway, MD MBA, Jaroslaw P. Maciejewski, PhD MD FACP, Babal K Jha, PhD, Yogenthiran Saunthararajah, MD

Blood (2017) 130 (Supplement 1): 878.

https://doi.org/10.1182/blood.V130.Suppl_1.878.878

Published: 2017

Journal Articles

The Mechanism By Which Mutant Nucleophosmin (NPM1) Creates Leukemic Self-Renewal Is Readily Reversed

Xiaorong Gu, PhD, Reda Z. Mahfouz, MD, PhD, Quteba Ebrahem, Francis Enane, Tomas Radivoyevitch, PhD, Michael J. Clemente, M.S., Bartlomiej P Przychodzen, MSc, Zhenbo Hu, MD PhD, Ramesh Balusu, PhD, Claudiu V. Cotta, MD, David N. Wald, MDPhD, Yosef Landesman, PhD, Maria Paola Martelli, MD PhD, Brunangelo Falini, Jaroslaw P Maciejewski, MD PhD FACP, Yogenthiran Saunthararajah, MD

Blood (2016) 128 (22): 444.

https://doi.org/10.1182/blood.V128.22.444.444

Published: 2016

Journal Articles

Mechanisms of Resistance to 5-Azacytidine/Decitabine in MDS-AML and Pre-Clinical In Vivo Proof of Principle of Rational Solutions to Extend Response

Quteba Ebrahem, Reda Z. Mahfouz, MDPhD, Lisa Durkin, Mikkael A. Sekeres, MD MS, Anjali S. Advani, MD, Hetty E. Carraway, MD MBA, Sudipto Mukherjee, MD PhD, Betty K. Hamilton, MD, Aaron T. Gerds, MD MS, Ronald Sobecks, MD, Frederic J. Reu, MD, Eric D. Hsi, MD, Jaroslaw P. Maciejewski, MD PhD, Yogenthiran Saunthararajah, MD

Blood (2015) 126 (23): 678.

https://doi.org/10.1182/blood.V126.23.678.678

Published: 2015

Journal Articles

Splicing Factor 3b Subunit 1 (SF3B1) Heterozygous Mice Manifest a Hematologic Phenotype Similar To Low Risk Myelodysplastic Syndromes With Ring Sideroblasts

Valeria Visconte, PhD, Heesun J. Rogers, MD, PhD, Ali Tabarroki, MD, Li Zhang, Yvonne Parker, Edy Hasrouni, Reda Z Mahfouz, MD/PhD, Quteba Ebrahem, MD, Kyoichi Isono, Haruhiko Koseki, Anjali S. Advani, MD, Yogen Saunthararajah, M.D., Mikkael A. Sekeres, MD, MS, Daniel Lindner, John Barnard, Ramon V. Tiu, MD

Blood (2013) 122 (21): 259.

https://doi.org/10.1182/blood.V122.21.259.259

Published: 2013

Journal Articles

Runx1 Haploinsufficiency Permits Lineage-Commitment but Impairs Activation of a Key Late Differentiation Gene

Zhenbo Hu, MD, Kwok Peng Ng, PhD, Quteba Ebrahem, MD, Yogen Saunthararajah, MD

Blood (2011) 118 (21): 2442.

https://doi.org/10.1182/blood.V118.21.2442.2442

Published: 2011

Journal Articles

Runx1 Regulates Pu.1 Coactivator/Corepressor Exchange

Xiaorong Gu, PhD, Zhenbo Hu, MD, Quteba Ebrahem, MD, Kwok Peng Ng, PhD, Jack S Crabb, MS, John W Crabb, PhD, Yogen Saunthararajah, MD

Blood (2011) 118 (21): 2372.

https://doi.org/10.1182/blood.V118.21.2372.2372

Published: 2011

Journal Articles

Combining Tetrahydrouridine with Decitabine Addresses Malignant Cell Sanctuary in the Liver, a Tissue That Expresses High Levels of Cytidine Deaminase,

Quteba Ebrahem, MD, Reda Z Mahfouz, MD, Kwok Ng Peng, PhD, Yogen Saunthararajah, MD

Blood (2011) 118 (21): 3509.

https://doi.org/10.1182/blood.V118.21.3509.3509

Published: 2011

Journal Articles

Gender Is A Major Determinant of Cytidine Analogue Metabolism and May Contribute to Differences in Treatment Outcomes

Reda Z Mahfouz, MD, Ania Jankowska, PhD, Quteba Ebrahem, MD, Zhenbo Hu, MD, Kenneth K. Chan, Ph.D, Donald Lavelle, Ph.D., Joseph DeSimone, PhD, Mikkael A. Sekeres, MD, MS, Ramon V. Tiu, MD, BS, Jaroslaw P. Maciejewski, MD, PhD, Yogen Saunthararajah, M.D.

Blood (2011) 118 (21): 1434.

https://doi.org/10.1182/blood.V118.21.1434.1434

Published: 2011

Journal Articles

EZH2 Is Either Mutated or Downregulated in Patients with Loss of Heterozygosity of Chromosome 7/7q and Leads to Epigenetic Dysregulation Via Histone H3K27.

Hideki Makishima, MD, PhD, Shahper N Khan, PhD, Anna M Jankowska, PhD, Yuka Sugimoto, MD, Zhenbo Hu, MD, Venugopalan Cheriyath, PhD, Reda Mahfouz, MD, Quteba Ebrahem, MD, Sergei Vatolin, PhD, Yogen Saunthararajah, MD, Mikkael A. Sekeres, MD, MS, Jaroslaw P Maciejewski, MD, PhD, FACP

Blood (2011) 118 (21): 228.

https://doi.org/10.1182/blood.V118.21.228.228

Published: 2011

Journal Articles

Effective and Non-Cytotoxic p53 Independent Epigenetic-Differentiation Therapy In Xeno-Transplant Models of Human Acute Myeloid Leukemia

Kwok Peng Ng, PhD, Quteba Ebrahem, MD, Soledad Negrotto, PhD, Reda Mahfouz, MD, Kevin Link, PhD, Zhenbo Hu, MD, Xiaorong Gu, PhD, Anjali Advani, MD, Matt Kalaycio, MD, Mikkael A. Sekeres, MD, MS, Edward A. Copelan, MD, Jaroslaw P Maciejewski, MD, PhD, FACP, James C. Mulloy, PhD, Yogenthiran Saunthararajah, MD

Blood (2010) 116 (21): 3309.

https://doi.org/10.1182/blood.V116.21.3309.3309

Published: 2010

Journal Articles

Identification of Oncogenic EZH2 Mutations In Myelodysplastic Syndromes and Related Myeloid Malignancies

Hideki Makishima, MD, PhD, Ania Jankowska, MSC, Ramon V. Tiu, MD, Hadrian Szpurka, PhD, MSC, Yuka Sugimoto, MD, PhD, Quteba Ebrahem, MD, Zhenbo Hu, MD, Reda Mahfouz, MD, Yogen Saunthararajah, MD, Kathryn Guinta, Mehdi Keddache, MSC, Christine L. O'Keefe, PhD, Mikkael A. Sekeres, MD, MS, Alan F. List, Michael A McDevitt, MD, PhD, Jaroslaw P Maciejewski, MD, PhD, FACP

Blood (2010) 116 (21): 607.

https://doi.org/10.1182/blood.V116.21.607.607

Published: 2010

NARROW

The Mechanisms By Which Mutant-NPM1 Uncouples Differentiation from Proliferation Are Reversed By Several Drugs, Enabling Rational Multi-Component Non-Cytotoxic Differentiation Therapy

The Mechanism By Which Mutant Nucleophosmin (NPM1) Creates Leukemic Self-Renewal Is Readily Reversed

Mechanisms of Resistance to 5-Azacytidine/Decitabine in MDS-AML and Pre-Clinical In Vivo Proof of Principle of Rational Solutions to Extend Response

Splicing Factor 3b Subunit 1 (SF3B1) Heterozygous Mice Manifest a Hematologic Phenotype Similar To Low Risk Myelodysplastic Syndromes With Ring Sideroblasts

Runx1 Haploinsufficiency Permits Lineage-Commitment but Impairs Activation of a Key Late Differentiation Gene

Runx1 Regulates Pu.1 Coactivator/Corepressor Exchange

Combining Tetrahydrouridine with Decitabine Addresses Malignant Cell Sanctuary in the Liver, a Tissue That Expresses High Levels of Cytidine Deaminase,

Gender Is A Major Determinant of Cytidine Analogue Metabolism and May Contribute to Differences in Treatment Outcomes

EZH2 Is Either Mutated or Downregulated in Patients with Loss of Heterozygosity of Chromosome 7/7q and Leads to Epigenetic Dysregulation Via Histone H3K27.

Effective and Non-Cytotoxic p53 Independent Epigenetic-Differentiation Therapy In Xeno-Transplant Models of Human Acute Myeloid Leukemia

Identification of Oncogenic EZH2 Mutations In Myelodysplastic Syndromes and Related Myeloid Malignancies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only